Search

Your search keyword '"Emily K. Hess"' showing total 2 results
Start Over Author "Emily K. Hess" Topic equine
2 results on '"Emily K. Hess"'

1. Blood glucose and insulin concentrations after alpha‐2‐agonists administration in horses with and without insulin dysregulation

Author

Janice E. Kritchevsky, Genevieve S. Muir, Dakota H. Z. Leschke, Jack K. Hodgson, Emily K. Hess, and Francois‐Rene Bertin

Subjects
detomidine, endocrinology, equine, metabolism, pancreas, xylazine, Veterinary medicine, SF600-1100
Abstract

Abstract Background In metabolically stable horses, alpha‐2‐agonists suppress insulin secretion with transient hyperglycemia and rebound hyperinsulinemia. In horses with insulin dysregulation (ID), the effect of alpha‐2‐agonists has not been investigated; however, both the alpha‐2‐agonist‐induced suppression of insulin secretion and rebound hyperinsulinemia could have clinical relevance. Hypothesis/Objectives In horses with ID, alpha‐2‐agonists will alter insulin and glucose dynamics. Animals Seven horses with ID and 7 control horses. Methods In this randomized crossover study, xylazine hydrochloride (1.1 mg/kg) or detomidine hydrochloride (30 μg/kg) were administered IV, and blood was collected for glucose and insulin concentrations at 0, 15, 30, 45, 60, 90, 120, 150, 180, and 300 minutes after administration. Horses received each drug in a random order with a 24‐hour washout period between drugs. Percent change in glucose and insulin concentrations was compared between groups, drugs, and over time with P

Published
2020
Full Text
View/download PDF

2. Blood glucose and insulin concentrations after alpha‐2‐agonists administration in horses with and without insulin dysregulation

Author

Emily K. Hess, Genevieve S. Muir, Jack K. Hodgson, Francois-Rene Bertin, Dakota H. Z. Leschke, and Janice E. Kritchevsky

Subjects
Blood Glucose, Male, Xylazine, medicine.medical_specialty, medicine.drug_class, medicine.medical_treatment, Conscious Sedation, Standard Article, Endocrinology, Internal medicine, Hyperinsulinemia, Adrenergic alpha-2 Receptor Agonists, Medicine, Endocrine system, Animals, Hypnotics and Sedatives, Insulin, pancreas, Horses, equine, Detomidine, lcsh:Veterinary medicine, Cross-Over Studies, General Veterinary, detomidine, business.industry, Imidazoles, medicine.disease, Crossover study, Standard Articles, Sedative, lcsh:SF600-1100, Alpha-2 adrenergic receptor, Female, EQUID, business, metabolism, medicine.drug
Abstract

Background In metabolically stable horses, alpha‐2‐agonists suppress insulin secretion with transient hyperglycemia and rebound hyperinsulinemia. In horses with insulin dysregulation (ID), the effect of alpha‐2‐agonists has not been investigated; however, both the alpha‐2‐agonist‐induced suppression of insulin secretion and rebound hyperinsulinemia could have clinical relevance. Hypothesis/Objectives In horses with ID, alpha‐2‐agonists will alter insulin and glucose dynamics. Animals Seven horses with ID and 7 control horses. Methods In this randomized crossover study, xylazine hydrochloride (1.1 mg/kg) or detomidine hydrochloride (30 μg/kg) were administered IV, and blood was collected for glucose and insulin concentrations at 0, 15, 30, 45, 60, 90, 120, 150, 180, and 300 minutes after administration. Horses received each drug in a random order with a 24‐hour washout period between drugs. Percent change in glucose and insulin concentrations was compared between groups, drugs, and over time with P

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results